vs
Side-by-side financial comparison of Embecta Corp. (EMBC) and Frontdoor, Inc. (FTDR). Click either name above to swap in a different company.
Frontdoor, Inc. is the larger business by last-quarter revenue ($432.0M vs $261.2M, roughly 1.7× Embecta Corp.). Embecta Corp. runs the higher net margin — 16.9% vs 0.2%, a 16.7% gap on every dollar of revenue. On growth, Frontdoor, Inc. posted the faster year-over-year revenue change (12.8% vs -0.3%). Frontdoor, Inc. produced more free cash flow last quarter ($95.0M vs $16.6M). Over the past eight quarters, Frontdoor, Inc.'s revenue compounded faster (6.9% CAGR vs -4.6%).
Embecta Corp. is a global medical technology company focused on diabetes care solutions. It designs, manufactures and distributes a full portfolio of products including insulin pen needles, syringes, infusion set components and related delivery devices, serving patients, healthcare providers and biopharmaceutical partners across North America, Europe, Asia Pacific and other major markets.
Frontdoor, Inc. operates a leading U.S.-focused home services and protection platform. It offers customizable home warranty plans covering repairs and replacements for household appliances, HVAC, plumbing, and electrical systems, plus on-demand access to a network of pre-vetted local service professionals for residential maintenance and repairs.
EMBC vs FTDR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $261.2M | $432.0M |
| Net Profit | $44.1M | $1.0M |
| Gross Margin | 61.9% | 49.3% |
| Operating Margin | 31.9% | 0.5% |
| Net Margin | 16.9% | 0.2% |
| Revenue YoY | -0.3% | 12.8% |
| Net Profit YoY | — | -88.9% |
| EPS (diluted) | $0.74 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $261.2M | $432.0M | ||
| Q3 25 | $264.0M | $618.0M | ||
| Q2 25 | $295.5M | $617.0M | ||
| Q1 25 | $259.0M | $426.0M | ||
| Q4 24 | $261.9M | $383.0M | ||
| Q3 24 | $286.1M | $540.0M | ||
| Q2 24 | $272.5M | $542.0M | ||
| Q1 24 | $287.2M | $378.0M |
| Q4 25 | $44.1M | $1.0M | ||
| Q3 25 | $26.4M | $106.0M | ||
| Q2 25 | $45.5M | $111.0M | ||
| Q1 25 | $23.5M | $37.0M | ||
| Q4 24 | $0 | $9.0M | ||
| Q3 24 | $14.6M | $100.0M | ||
| Q2 24 | $14.7M | $92.0M | ||
| Q1 24 | $28.9M | $34.0M |
| Q4 25 | 61.9% | 49.3% | ||
| Q3 25 | 60.0% | 57.1% | ||
| Q2 25 | 66.7% | 57.7% | ||
| Q1 25 | 63.4% | 55.2% | ||
| Q4 24 | 60.0% | 48.0% | ||
| Q3 24 | 60.7% | 56.7% | ||
| Q2 24 | 69.8% | 56.5% | ||
| Q1 24 | 64.6% | 51.6% |
| Q4 25 | 31.9% | 0.5% | ||
| Q3 25 | 21.4% | 23.0% | ||
| Q2 25 | 31.8% | 23.7% | ||
| Q1 25 | 24.3% | 11.3% | ||
| Q4 24 | 11.0% | 1.6% | ||
| Q3 24 | 9.2% | 24.8% | ||
| Q2 24 | 20.5% | 22.9% | ||
| Q1 24 | 13.6% | 11.9% |
| Q4 25 | 16.9% | 0.2% | ||
| Q3 25 | 10.0% | 17.2% | ||
| Q2 25 | 15.4% | 18.0% | ||
| Q1 25 | 9.1% | 8.7% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 5.1% | 18.5% | ||
| Q2 24 | 5.4% | 17.0% | ||
| Q1 24 | 10.1% | 9.0% |
| Q4 25 | $0.74 | $0.03 | ||
| Q3 25 | $0.44 | $1.42 | ||
| Q2 25 | $0.78 | $1.48 | ||
| Q1 25 | $0.40 | $0.49 | ||
| Q4 24 | $0.00 | $0.10 | ||
| Q3 24 | $0.24 | $1.30 | ||
| Q2 24 | $0.25 | $1.18 | ||
| Q1 24 | $0.50 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.3M | $566.0M |
| Total DebtLower is stronger | — | $1.1B |
| Stockholders' EquityBook value | $-613.1M | $242.0M |
| Total Assets | $1.1B | $2.1B |
| Debt / EquityLower = less leverage | — | 4.73× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $201.3M | $566.0M | ||
| Q3 25 | $225.5M | $563.0M | ||
| Q2 25 | $230.6M | $562.0M | ||
| Q1 25 | $209.3M | $506.0M | ||
| Q4 24 | $210.0M | $436.0M | ||
| Q3 24 | $267.5M | $375.0M | ||
| Q2 24 | $275.1M | $419.0M | ||
| Q1 24 | $299.8M | $378.0M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $1.6B | $565.0M | ||
| Q2 24 | — | $569.0M | ||
| Q1 24 | — | $573.0M |
| Q4 25 | $-613.1M | $242.0M | ||
| Q3 25 | $-650.6M | $316.0M | ||
| Q2 25 | $-669.6M | $254.0M | ||
| Q1 25 | $-736.2M | $198.0M | ||
| Q4 24 | $-768.8M | $239.0M | ||
| Q3 24 | $-738.3M | $261.0M | ||
| Q2 24 | $-763.7M | $214.0M | ||
| Q1 24 | $-769.6M | $162.0M |
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $1.2B | $2.2B | ||
| Q1 25 | $1.1B | $2.1B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.3B | $1.2B | ||
| Q1 24 | $1.2B | $1.1B |
| Q4 25 | — | 4.73× | ||
| Q3 25 | — | 3.64× | ||
| Q2 25 | — | 4.56× | ||
| Q1 25 | — | 5.88× | ||
| Q4 24 | — | 4.90× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | — | 2.66× | ||
| Q1 24 | — | 3.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.2M | $101.0M |
| Free Cash FlowOCF − Capex | $16.6M | $95.0M |
| FCF MarginFCF / Revenue | 6.4% | 22.0% |
| Capex IntensityCapex / Revenue | 0.2% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.39× | 101.00× |
| TTM Free Cash FlowTrailing 4 quarters | $205.8M | $390.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.2M | $101.0M | ||
| Q3 25 | $84.0M | $64.0M | ||
| Q2 25 | $81.2M | $127.0M | ||
| Q1 25 | $31.8M | $124.0M | ||
| Q4 24 | $-5.3M | $58.0M | ||
| Q3 24 | $26.6M | $25.0M | ||
| Q2 24 | $-2.1M | $103.0M | ||
| Q1 24 | $24.3M | $84.0M |
| Q4 25 | $16.6M | $95.0M | ||
| Q3 25 | $76.7M | $58.0M | ||
| Q2 25 | $80.8M | $120.0M | ||
| Q1 25 | $31.7M | $117.0M | ||
| Q4 24 | $-6.8M | $50.0M | ||
| Q3 24 | — | $16.0M | ||
| Q2 24 | $-11.8M | $91.0M | ||
| Q1 24 | $20.9M | $74.0M |
| Q4 25 | 6.4% | 22.0% | ||
| Q3 25 | 29.1% | 9.4% | ||
| Q2 25 | 27.3% | 19.4% | ||
| Q1 25 | 12.2% | 27.5% | ||
| Q4 24 | -2.6% | 13.1% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | -4.3% | 16.8% | ||
| Q1 24 | 7.3% | 19.6% |
| Q4 25 | 0.2% | 1.4% | ||
| Q3 25 | 2.8% | 1.0% | ||
| Q2 25 | 0.1% | 1.1% | ||
| Q1 25 | 0.0% | 1.6% | ||
| Q4 24 | 0.6% | 2.1% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 3.6% | 2.2% | ||
| Q1 24 | 1.2% | 2.6% |
| Q4 25 | 0.39× | 101.00× | ||
| Q3 25 | 3.18× | 0.60× | ||
| Q2 25 | 1.78× | 1.14× | ||
| Q1 25 | 1.35× | 3.35× | ||
| Q4 24 | — | 6.44× | ||
| Q3 24 | 1.82× | 0.25× | ||
| Q2 24 | -0.14× | 1.12× | ||
| Q1 24 | 0.84× | 2.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
FTDR
| Renewals | $332.0M | 77% |
| Other | $43.0M | 10% |
| Direct To Consumer Home Service Plan Contracts | $30.0M | 7% |
| Real Estate Home Service Plan Contracts | $27.0M | 6% |
